High mobility group box 1 (HMGB1) is a 25-kDa chromatin-associated protein that aids in transcription and DNA repair by directly binding to DNA and altering its conformation. Additionally, HMGB1 can act as an extracellular ligand. When released from dying or stressed cells, HMGB1 binds to the RAGE receptor and activates the p42/44 MAP kinase (MAPK) cascade. HMGB1 is overexpressed in many types of cancer and frequently associated with tumor stage and metastasis. This has predominantly been attributed to an autocrine function that drives MAPK pathway activity. However, by using tumor cells with activating MAPK pathway mutations, we have identified a role for HMGB1 in promoting metastasis and tumor growth that is independent of this pathway. In the absence of HMGB1, these tumor cells show defective in vitro migration as well as reduced metastasis and tumor growth in vivo despite high p42/44 phosphorylation. We found that semaphorin 3A (SEMA3A), previously shown to act as a suppressor of angiogenesis and migration, was highly increased during expression in the absence of HMGB1. SEMA3A/HMGB1 double knockdown rescued the migration defect in HMGB1 single knockdown cells. HMGB1 bound at the semaphorin 3A genomic locus, promoted hetrochromatin formation, and decreased occupancy of acetylated histones. Based on human tumor gene expression databases, HMGB1 was significantly inversely correlated with SEMA3A, suggesting that this mechanism may be more widely relevant in different cancer types.
INTRODUCTION
High mobility group box 1 (HMGB1) is a 25-kDa DNA-binding protein that is overexpressed in various cancers. Its expression is often associated with poor prognosis, higher tumor grade and metastasis. 1 In a colon cancer study, HMGB1 was shown to be overexpressed in tumor tissue compared with adjacent normal tissue in 90% of patients. 2 In addition, a causative role for HMGB1 in promoting colon carcinogenesis was shown experimentally. 3 Similar results have been reported for hepatocellular carcinoma, 4 nasopharyngeal carcinoma, 5 prostate cancer, 6 melanoma 7 and breast cancer. 8 The high prevalence of HMGB1 upregulation in diverse tumor types suggests a critical role in carcinogenesis; however, despite a strong correlation between HMGB1 expression and negative clinical outcome, the mechanism by which HMGB1 promotes tumor growth and metastasis remains unclear.
HMGB1 binds to DNA without sequence specificity and aids in distorting the DNA structure to allow access for repair and transcription proteins. 9 ,10 HMGB1-deficient mice die within 24 h after birth from hypoglycemia as a result of defective glucocorticoid-mediated transcription.
11 HMGB1 interacts with various transcription factors, including NFkB members, 12 p53 13 and the TATA-binding protein. 14 Interactions with these factors can promote or repress transcription depending on the cellular context.
In addition to its roles in the nucleus, HMGB1 can also act as a ligand when released from dying or stressed cells. HMGB1 binds to the receptor for advanced glycation end products (RAGE) or toll-like receptors (TLR) 2/4, which are expressed on many types of immune and tumor cells. HMGB1 binding to RAGE results in activation of the Ras MAP kinase pathway and increased levels of phosphorylated p42/44 (ERK1/2). 15 The pro-tumor effects of HMGB1 are often attributed to its extracellular role, through stimulation of the MAPK pathway via RAGE binding. 16 Functionally, preventing extracellular release of HMGB1 by drug treatment or blocking HMGB1 signaling with antibodies can reduce tumor growth and metastasis in some experimental models of cancer. 3, 17, 18 In addition, RAGE-deficient mice are resistant to tumor formation in chemical carcinogeninduced skin cancer models, 19 and RAGE expression is also often associated with poor clinical outcome and metastasis. The HMGB1-RAGE-MAPK signaling axis thus appears to be important in many cancers. However, tumor types with frequent activating mutations in the MAPK pathway, such as colon cancer and melanoma, still are often found to overexpress HMGB1, indicating a possible MAPK-independent function.
Here, we have tested the effect of depleting HMGB1 in cell lines with constitutive MAPK activity. We found that HMGB1-deficient cells were impaired in migration in vitro and metastasis in vivo, despite maintaining high levels of phosphorylated p42/44. Further experiments revealed a role for HMGB1 in transcriptionally repressing the semaphorin 3A (SEMA3A) locus, a gene previously described to suppress cell migration and angiogenesis. A functional connection between HMGB1 and SEMA3A was shown by a partial rescue of the migration defect in HMGB1 knockdown cells on dual knockdown of SEMA3A.
RESULTS

HMGB1 knockdown alters cell morphology and decreases in vitro migration in cells with an activated MAPK pathway
To identify MAPK-independent functions of HMGB1, we used a lentiviral short hairpin RNA (shRNA) system to stably knock-down HMGB1 in cancer cells with activating mutations in the MAPK pathway. The MDA-MB-231 breast cancer cell line had mutations in K-Ras and B-Raf resulting in high basal MAPK activity, while the MDA-MB-435 cells were derived from a melanoma with an activating B-Raf mutation.
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HMGB1 protein expression was reduced by 70-92% as compared with cells with non-silencing shRNA (Figure 1a ) after a minimum of 1 week growing in culture with puromycin selection. HMGB1 knockdown did not reduce basal MAPK signaling in these cell lines as judged by levels of phosphorylated ERK1/2 (Figure 1a) , and in vitro proliferation was not affected (Figure 1b) . However, depletion of HMGB1 caused the cells to adopt a more epithelial morphology with less extended processes in two-dimensional tissue culture (Figure 1c) . Cells with diminished HMGB1 expression also showed reduced F-actin foci at the cell periphery and significantly reduced cell scattering in a colony formation assay (Figure 1c ), but did not affect colony-forming ability (data not shown). HMGB1-depleted cells were also deficient in migration as measured in a scratch assay (Figure 1d ).
HMGB1 is required for tumor cell colonization from the circulatory system in vivo Tumor metastasis is thought to occur in several steps. Initially, the cells must detach from the primary tumor and degrade the stroma to gain access to the circulatory system. Once in circulation, the cells must adhere to the endothelial cell wall and migrate through the surrounding tissue to arrive at and populate new organ sites. HMGB1 expression is correlated with metastasis in human tumors 21 and has been shown to be required for aspects of the metastatic process in some experimental models. 16 Because our in vitro results suggested a deficiency in migration, we tested whether HMGB1 knockdown also affected in vivo metastatic capacity. To investigate metastatic potential, we used a system that has been described previously for MDA-MB-231 cells. 22 In this colonization/metastasis model, the cells are injected into the circulatory system of an immune-compromised mouse and allowed to invade and populate new locations, therefore recapitulating the later steps of metastasis.
MDA-MB-231 luciferase-expressing cells with HMGB1 knockdown or control shRNA were injected intracardially into nude mice. The resulting tumors were allowed to grow for 10-12 weeks and counted in each mouse using bioluminescence. To account for differences in rates of tumor growth and thus detection between HMGB1 knockdown and control tumors, metastases were counted at a time point normalized to equal bioluminescence of the largest tumor. HMGB1 knockdown cells formed 40% fewer tumors in this assay (P ¼ 0.01) (Figure 2a ). There was no preference for sites of metastases between cell groups, with bone, kidney and lung constituting the majority in both groups (data not shown).
HMGB1 is required for tumor growth in vivo
Previous models have shown that HMGB1 is required for in vivo tumor growth owing to its ability to drive MAPK activation. Using our system, we tested whether HMGB1 was still required for tumor growth in the presence of a constitutively active MAPK pathway. Stable populations of MDA-MB-231 cells carrying a luciferase reporter gene and HMGB1 knockdown or control shRNA were orthotopically injected into the mammary fat pads of 6-week-old SCID mice and monitored for growth up to 8 weeks. Cells expressing HMGB1 shRNA showed a significantly reduced growth rate as measured by bioluminescent signal (Figure 2b) . Consistent with the in vitro data, HMGB1-deficient tumors did not have significantly reduced levels of phosphorylated ERK1/2 as judged by western blot (Figure 2c) . Because HMGB1 has previously been shown to contribute to angiogenesis in other systems, 23 we next investigated the state of tumor-associated endothelial cells in HMGB1-deficient tumors. In the absence of HMGB1, tumors showed decreased CD31 þ cell infiltration (Figure 2d ). Macroscopically and by hematoxylin and eosin staining, it was observed HMGB1 knockdown tumors had a more disorganized structure and increased necrosis (data not shown).
HMGB1 knockdown alters the expression of 122 genes Given that the phenotypes we observed could not be explained by reduced MAPK signaling, we sought to investigate the transcriptional functions of HMGB1. HMGB1 is known to cooperate with various transcription factors to promote or repress gene expression depending on the cellular context. We performed a transcriptional microarray in triplicate using HMGB1 knockdown or control cell populations in log phase growth. We chose to use cells in log phase as opposed to resting to mimic conditions present when cells had pronounced morphological differences and decreased scattering. Using a cutoff of 1.5-fold difference in expression and a q-value o0.05 (Po0.001), we identified 25 genes that were downregulated by HMGB1 knockdown and 97 genes that were upregulated (Table 1 ). Among the top upregulated genes were two members of the class 3 semaphorin family, semaphorin 3A (SEMA3A) and semaphorin 3E (SEMA3E).
Class 3 semaphorins are secreted proteins that act as inhibitors of angiogenesis and cellular migration. 24 They are often downregulated in more aggressive tumors 25 and suppress tumor growth and metastasis in experimental models. 26 The loss of their expression is increasingly being recognized as a critical step in the evolution of more aggressive tumors. SEMA3A is the best-characterized member of this family. SEMA3A binds to neuropilin 1 and promotes GAP activity of Plexin A1, which through R-Ras leads to inactivation of Beta1 integrin. 27 Figure 1. HMGB1 depletion causes loss of F-actin processes and migratory behavior without reducing basal P-ERK levels in MDA-MB-231 and MDA-MB-435 cells. (a) HMGB1 can be depleted without decreasing P-ERK levels. MDA-MD-231 and MDA-MB-435 cells were stably depleted of HMGB1 with lentiviral shRNA using control or two independent HMGB1 targeting shRNAs. After 1-3 weeks of selection, cells were analyzed by western blot for HMGB1 and P-ERK levels using Licor Odyssey software. (b) HMGB1 knockdown does not affect proliferation in vitro. MDA-MB-231 cells were transduced with control shRNA or two independent HMGB1 shRNAs. After 1-3 weeks of selection, cells were seeded into sixwell plates and counted with a Coulter counter in triplicate. Media was changed at 3 days. (c) HMGB1 knockdown changes cell morphology, reduces F-actin foci and diminishes scattering behavior. (Top) Control and HMGB1 knockdown cells were imaged by phase contrast microscopy to illustrate morphological differences. (Middle) Cells were stained with rhodamine-phalloidin to outline F-actin. (Bottom) Cells were seeded by serial dilution to B100 cells/well in six-well plates. Single cells were allowed to grow into colonies over 2-4 weeks and fixed with crystal violet stain. Colonies were then analyzed for dispersion during growth or 'scattering' . For each condition, 10 different fields of view containing 4-9 colonies each were sorted into 'scattered' or 'non-scattered' groups and quantified. (d) HMGB1 knockdown decreases in vitro migration in a scratch assay. Control or HMGB1 knockdown cells were seeded into six-well plates overnight and scratched the next day. Images were collected at the time points listed. Relative migration was quantified by measuring the distance between scratch edges for 10 different points and compared with time 0.
Additionally, SEMA3A can initiate F-actin depolymerization through Plexin-A1-MICAL interactions. 28 Because of this close link between the functions of semaphorins and the phenotype of the HMGB1 knockdown, we chose to further investigate this potential connection.
HMGB1 silences SEMA3A expression To validate our array data, semaphorin gene expression during HMGB1 knockdown was examined with real-time PCR in different tumor cell lines, including one melanoma, one lung and two breast cancer cell lines in addition to MDA-MB-231. These cell lines Although we identified HMGB1 as a repressor for SEMA3A in cell lines, it was not clear if this function was relevant in primary human tumors. To investigate a potential connection between HMGB1 and SEMA3A in primary tumors, we analyzed publicly available GEO profile transcriptional microarray data from various tumor types. Using microarray data from 23 primary breast tumors, we observed a significant inverse correlation between HMGB1 and SEMA3A (R 2 ¼ 0.23, P ¼ 0.02, Figure 3e ). A similar relationship was observed in a cohort of bladder tumors, with the more invasive samples from the bladder cancer data set showing high HMGB1 and low SEMA3A (Figure 3f ).
SEMA3A knockdown restores F-actin localization, invasive morphology and in vitro migration of HMGB1-deficient cells HMGB1 knockdown caused a significant change in cell morphology and migration and also altered the expression of 122 genes, including SEMA3A. To determine the contribution of SEMA3A upregulation to the phenotype of HMGB1 knockdown cells, we performed double knockdowns of HMGB1 and SEMA3A (Figure 4a ). Double-knockdown cells largely regained the invasive morphology of the parent cells. F-actin was restored to the leading edges of cell processes and scattering ability in vitro was partially restored (Figure 4b ). As judged by scratch assay, migration was also significantly rescued by knockdown of SEMA3A (Figure 4c ). Although these in vitro characteristics were rescued by double knockdown, we were unable to observe a difference in metastatic potential in vivo. This was largely due to the fact that double-knockdown cells showed a reduced growth rate and poor adhesion. This is likely due to adaptations that occur in response to loss of HMGB1 and widespread gene expression changes. Nonetheless, our data indicates that HMGB1-mediated silencing of SEMA3A partially contributes to the invasive phenotype of tumor cells. This observation is consistent with previous studies that show an essential role for SEMA3A in suppressing experimental models of metastasis and invasive cell morphology. 26 These data, in addition to the correlation between HMGB1 and SEMA3A in primary tumors, led us to further investigate the mechanism of HMGB1-mediated SEMA3A silencing. (Figure 5a ). We also tested recombinant HMGB1 at a concentration previously shown to promote P-ERK-dependent cell migration in fibroblasts. 29 Although in this experiment the level of SEMA3A upregulation was less, it was still significantly increased even in the presence of recombinant HMGB1. These data suggest that nuclear HMGB1 is responsible for SEMA3A silencing, and led us to further investigate the mechanism of silencing at the SEMA3A genomic locus.
The mechanism of nuclear HMGB1-mediated transcription stimulation has been well characterized and involves the intrinsic ability of HMGB1 to bend DNA, thus allowing greater access to transcription factors. 30 In contrast, the mechanism of HMGB1-mediated gene silencing is much less understood. HMGB1 has previously been reported to associate with silenced chromatin at the TNFa promoter in models of endotoxin tolerance. 31 To investigate the mechanism of HMGB1-mediated gene silencing further, we focused on a region of SEMA3A between the transcription start site and 2 kb upstream ( Figure 6b A549 lung cancer cells show altered migration and morphology after HMGB1 knockdown that is restored to the parental phenotype by the additional knockdown of SEMA3A. As in panel a, HMGB1 was depleted singly or in combination with SEMA3A. Migration was analyzed by scattering assay, and F-actin localization was visualized with phalloidin-rhodamine staining. Scattering was quantified as described previously.
(c) Reduced MDA-MB-435 cell migration with HMGB1 knockdown can be rescued by additional SEMA3A knockdown. Cells were treated as described above and migration was analyzed by a scratch assay as in Figure 1 . control, we analyzed the homologous region in the SEMA4F gene, whose expression was not affected by HMGB1 knockdown in our microarray analysis. HMGB1 bound at roughly equal levels to both HMGB1-dependent SEMA3A and HMGB1-independent SEMA4F, as revealed by chromatin immunoprecipitation (ChIP) experiments and QPCR analysis (Figure 6c ). This suggested that promoter binding alone is not sufficient to explain the locus-specific transcriptional repression by HMGB1 and is consistent with previous studies showing HMGB1 binding to DNA without gene specificity. 32 We next investigated whether HMGB1 altered chromatin structure in a locus-specific manner. To study this, we examined chromatin sensitivity to DNAse digestion in control or HMGB1 shRNA-expressing cells. Open chromatin or euchromatin is characterized as being more sensitive to nuclease digestion and more transcriptionally active, while closed chromatin or heterochromatin is resistant to digestion and associated with silenced genes. As shown in Figure 6d , in the absence of HMGB1, the SEMA3A promoter became sensitized to DNAse digestion while the SEMA4F promoter was not significantly affected.
Heterochromatin is often associated with several types of epigenetic modification, including histone hypoacetylation and DNA methylation. To analyze the potential epigenetic regulation of SEM3A expression, we first used chemical inhibitors of histone deacetylases and DNA methyltransferases, trichostatin A and 5-Azacytidine, respectively. 5-Azacytidine treatment increased expression of SEMA3A mRNA significantly and showed an even greater increase when used in combination with trichostatin A (Figure 6a ).
To test if HMGB1 altered the presence of acetylated histones in a locus-specific manner, we used ChIP with an antibody to acetylated histone H4 or H3 with or without HMGB1 knockdown. As shown in Figure 6e , loss of HMGB1 increased acetylated histone H4 (Ac-H4) occupancy at the SEMA3A promoter by ninefold compared with IgG control immunoprecipitation. In contrast, binding of Ac-H4 increased to a lesser degree at the SEMA4F promoter at about threefold. A similar SEMA3A-specific enrichment was observed for acetylated histone H3 in the absence of HMGB1 (Figure 6f ).
To further investigate the impact of HMGB1 on DNA methylation, we performed bisulfite sequencing on a region near the SEMA3A promoter (Figure 7a ). Although we found no difference in CpG methylation between control and HMGB1 knockdown (data not shown), we found significantly reduced non-CpG cytosine methylation at two different residues in MDA-MB-231 and SUM159PT cells (Figure 7a) . Strikingly, both of these cytosines occurred in almost the same relative position downstream of a CCCTC-binding factor (CTCF) putative recognition sequence. To test if CTCF binding was affected by HMGB1 knockdown, we performed a ChIP, as in Figure 6 . Interestingly, although CTCF is often thought of as a transcriptional repressor, HMGB1 knockdown enhanced the binding of CTCF upstream of SEMA3A (Figure 7b ).
DISCUSSION
In this work, we identified a role for HMGB1 in promoting tumor growth, cell migration and metastasis that is independent of MAPK activity but at least partly mediated by transcriptional repression of SEMA3A. SEMA3A, and generally the class 3 semaphorins are increasingly being recognized as key suppressors of tumor growth and metastasis. Our findings suggest that overexpression of HMGB1 is one mechanism that contributes to semaphorin silencing in cancer.
In vivo, we showed a significantly reduced growth rate of HMGB1 knockdown tumors despite no difference in proliferation in vitro. This reduction in growth correlated with increased necrosis and reduced angiogenesis in the HMGB1-deficient tumors. These tumors also showed higher levels of SEMA3A in vivo. SEMA3A is a well-established inhibitor of angiogenesis in various experimental systems. Although we did not formally investigate the possibility here, it is plausible that increased SEMA3A expression contributed to the reduced angiogenesis and defective growth of HMGB1 knockdown tumors. Although SEMA3A upregulation contributed to the HMGB1 knockdown phenotype, it was only one of 122 genes targeted by HMGB1. It is likely that the other HMGB1 targets also contribute to the pro-tumor phenotype associated with HMGB1 overexpression. It is of note that although HMGB1 has no intrinsic sequence specificity in binding DNA, we nonetheless observed altered expression at only specific gene targets during knockdown. We and others have shown that HMGB1 is not differentially enriched for binding at specific loci, regardless of its differential effect on specific gene expression. It is possible that HMGB1 achieves gene specificity due to being a required cofactor only at certain loci, making these genes especially sensitive to HMGB1 expression levels. Our studies show that HMGB1 participates in gene silencing through driving chromatin remodeling that is associated with decreased binding of acetylated histones H3 and H4. These findings suggest that those gene targets that are particularly sensitive to histone deacetylase inhibitors may also be sensitive to HMGB1 inhibition. We have also observed a decrease in non-CpG cytosine methylation on HMGB1 knockdown in two cell lines. This occurred in proximity to a CTCF-binding sequence in both cases and HMGB1 knockdown caused an increase in CTCF occupancy upstream of SEMA3A. Although CTCF has been described as a transcriptional repressor, in this case increased CTCF binding correlated with transcriptional activation of SEMA3A. Future studies will be needed to examine the relationship between cytosine methylation, CTCF binding and SEMA3A expression.
The inverse correlation between HMGB1 and SEMA3A that we observed in primary tumor transcriptional microarray data suggest that HMGB1-mediated repression of SEMA3A might occur in human tumors. Although this is only correlative data, in light of the causative and mechanistic role for HMGB1 in cell lines, this correlation may be functionally relevant.
HMGB1 has been recognized as a tumor-promoting factor for many years, but the majority of work has focused on its role as an activator for the MAPK pathway. Several proposed therapies seek to neutralize, block release of or inhibit signaling by extracellular HMGB1. Our results shed light on the significant role nuclear HMGB1 has in promotion of tumor growth and metastasis, independently of its role as a ligand for MAPK activation. This suggests that future cancer therapies should consider targeting nuclear HMGB1 and emphasize the important pro-tumor functions of HMGB1 even in malignancies that harbor MAPK mutations.
MATERIALS AND METHODS
Cell lines
MDA-MB-231-luciferase cells were a gift from Dr Byron Hann. SUM159PT and HS578T cells were a gift from Dr Madhu Macrae. A549 cells were a gift from Dr Tony Karnezis. MDA-MB-435 cells were a gift from Dr Amy Young.
Western blotting and proteins
Polyclonal rabbit anti-HMGB1 was obtained from Abcam (Cambridge, MA, USA). Anti-SEMA3A was from ECM Biosciences (Versailles, KY, USA). Phospho-p42/44 and p42/44 were purchased from Cell Signaling (Beverly, MA, USA). Images were scanned and quantified using the Odyssey system and Licor imaging software (Lincoln, NE, USA). Recombinant HMGB1 was obtained from R&D Systems (Minneapolis, MN, USA).
Lentiviral shRNA transduction
Five bacterial clones carrying HMGB1-targeted shRNA sequences from the Mission shRNA consortium in the pLKO.1 vector were propagated overnight. DNA was then isolated using the Qiagen Maxiprep kit as per manufacturer's instructions (Qiagen, Hilden, Germany). DNA was transfected with Fugene into 293T cells in the following amounts: 4.2 mg shRNA, 0.4 mg VSVG, 3.7 mg GAG/POL, 3.7 mg REV. After 3 days of incubation at 37 1C, the virus-containing supernatant was removed and filtered through a 0.45-mm filter before being added to target cells. A volume of 4.5 mg/ml polybrene was added to aid in the infection. After 24 h, media was replaced with 6 mg/ml puromycin-containing media. Transduced cells were selected for by incubating in this media for a minimum of 1 week. Three sequences that resulted in efficient knockdown of HMGB1 were used in subsequent experiments:
One shRNA that did not have any effect on HMGB1 expression was used as a control vector:
Scattering assay
Cells were serially diluted into six-well plates to a final concentration of B50-100 cells per well. Cells were grown in 10% fetal bovine serum and Dulbecco's modified Eagle medium for 3-4 weeks, with media being changed every 3 days. After 3-4 weeks, colonies were imaged by light microscopy.
Scratch assay
Equal numbers of cells were seeded into six-well plates overnight with full media. Scratches were conducted with a 20-ml pipette tip and media was changed. Scratches were imaged every 3 h using a marked position to return to the same scratch on the plate over time.
F-actin staining
Cells were seeded overnight onto chamber slides and fixed the next day with 4% paraformaldehyde in PBS for 20 min. Cells were then washed and permeabilized with 1% Triton-X in PBS for 10 min. After washing, 5% goat serum was used to block for 1 h. Rhodamine conjugated to phalloidin was added at 1:500 in 5% goat serum in PBS. After 1-h incubation in the dark, slides were washed and stained with Hoechst dye.
Metastatic colonization assay
A total of 50 000 luciferase-expressing MDA-MB-231 cells were intracardially injected into 6-to 7-week-old nude-Foxn1nu mice (Harlan), as previously described. 22 Mice were imaged weekly using Xenogen software.
Tumor growth in vivo
Two million luciferase-expressing MDA-MB-231 cells were injected into the mammary fat pads of SCID/Beige (C57BL/6 background) mice obtained from Charles River Laboratories (Wilmington, MA, USA). Tumors were imaged weekly.
Immunohistochemistry
Tumors were removed from mice and fixed overnight at 4 1C in Z-fix solution (Anatech, Battle Creek, MI, USA). After subsequent dehydration and sectioning, slides were incubated with biotinylated rat anti-mouse CD31 (BD Biosciences, San Jose, CA, USA) overnight. Slides were developed using HRP conjugated to streptavidin (R&D Systems).
Microarray
RNA was isolated from cells with the RNEasy kit (Qiagen). Transcriptional microarray analysis was conducted with help from the David Gladstone Research Center Genome Core. Affymetrix Human Gene 1.0 chips were used in triplicate for each sample. Data was analyzed using the Exploratory Gene Association Network (EGAN) program (http://akt.ucsf.edu/EGAN/). 33 
Real-time PCR (RT-PCR)
RT-PCR for SEMA3A expression was performed with help from the UCSF Genome Core using the Taqman probes to HMGB1 and SEMA3A (Applied Biosystems, Foster City, CA, USA).
Chromatin immunoprecipitation
ChIP was performed as previously described. 34 Briefly, 500 mg of protein/ chromatin mixture was incubated with 4 mg antibody overnight at 4 1C. Antibodies used were as follows: anti-Myc (9E10) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CTCF (Abcam), mouse IgG isotype (Abcam), normal rabbit serum (Sigma, St Louis, MO, USA) and acetylated-H3 and H4 (Cell Signaling). After several washes, complexes were eluted and DNA cross-linking reversed. DNA was purified either by phenol-chloroform extraction or using the Bio-Rad ChIP DNA purification kit, per manufacturer's instructions (Bio-Rad, Berkeley, CA, USA).
RT-PCR for ChIP analysis was performed using SYBR green (Applied Biosystems). The amplification program used was as follows:
Step 1: 94 1C for 10 min
Step 2: 94 1C for 20 s
Step 3: 60 1C for 1 min Steps 2 and 3 were repeated for 50 cycles. The amplification signal was measured at Step 3, and dissociation curves were used to ensure single products.
The primers used for amplification of the regions in SEMA3A and SEMA4F were as follows: 
DNAse sensitivity assay
Analysis was performed using the Bio-Rad EpiQ kit as per manufacturer's instructions. Briefly, cells were seeded into 24-well plates overnight. Cells were permeabilized with a weak detergent and incubated with DNAse for 1 h at 37 1C. Genomic DNA was isolated with a kit (Qiagen) and analyzed by RT-PCR using the following program:
Step 1: 2 min at 94 1C
Step 2: 20 s at 94 1C
Step 3: 30 s at 54 1C
Step 4: 30 s at 70 1C Steps 2-4 were repeated for 60 cycles Bisulfite sequencing
Genomic DNA was isolated with a kit (Qiagen). DNA was then subjected to bisulfite conversion with the Epitect kit (Qiagen). Converted DNA was amplified using the following primers: 
